Featured Research

from universities, journals, and other organizations

Medication May Reduce Incidence, Severity Of Mouth Sores In Some Cancer Patients: Study

Date:
December 28, 2004
Source:
University Of North Carolina At Chapel Hill
Summary:
Results of a multicenter clinical trial reported in today’s (Dec. 16) issue of the New England Journal of Medicine showed that palifermin caused significant reduction in the rate, duration and severity of the oral mucositis, or mouth sores, that occur after intensive chemotherapy and radiotherapy given during stem cell transplant therapy for blood cancers.

CHAPEL HILL -- Cancer patients now have help with one of the most painful side effects of high-dose chemotherapy and radiotherapy.

Results of a multicenter clinical trial reported in today’s (Dec. 16) issue of the New England Journal of Medicine showed that palifermin caused significant reduction in the rate, duration and severity of the oral mucositis, or mouth sores, that occur after intensive chemotherapy and radiotherapy given during stem cell transplant therapy for blood cancers.

Depending on the treatment used, mucositis can affect nearly 100 percent of patients undergoing these intensive therapies.

"This is a major advance in the care of patients receiving high-dose therapy and stem cell transplantation, especially with treatments that cause severe mouth sores," said Dr. Tom Shea, professor of medicine in the University of North Carolina at Chapel Hill’s School of Medicine, director of UNC’s Bone Marrow and Stem Cell Transplantation Program and member of UNC Lineberger Comprehensive Cancer Center.

"This drug clearly reduces the frequency and severity of one of the most painful complications of transplant for many patients receiving this type of care," Shea added

UNC Hospitals and UNC Lineberger represented one of the 13 study sites for the trial sponsored by Amgen Inc.

The 212 cancer patients involved in this phase three trial were given either a placebo injection and standard care for mucositis, or injections of palifermin, a recombinant human keratinocyte growth factor manufactured by Amgen.

The study compared the rate of severe oral mucositis in the groups receiving palifermin with those treated with the placebo. There was a marked improvement in several key study outcomes: a 63 percent rate of severe mouth sores in the palifermin group versus 98 percent in the placebo group.

The duration of mucositis was reduced to an average of six days in the palifermin group versus nine days in the placebo group. The use of intravenous narcotics for pain relief was reduced by 60 percent in the palifermin group, and the use of intravenous-administered nutrition was reduced from 55 percent of participants in the placebo group to 31 percent of participants in the palifermin group.

Studies are under way to test the value of the medication in other treatment settings in which mucositis is likely to occur, Shea said.

Lead author of the study was Dr. Ricardo Spielberger of City of Hope National Medical Center in Duarte, Calif. Other participating institutions were UNC; Loyola University Medical Center in Maywood, Ill.; Fred Hutchinson Cancer Research Center in Seattle; State University of New York Upstate Medical University in Syracuse; the University of Minnesota at Minneapolis; Memorial Sloan-Kettering Cancer Center in New York City; Georgetown University Cancer Center in Washington, D.C.; the Northwest Marrow Transplant Center in Portland, Ore.; Sinai Hospital of Baltimore; the Medical College of Virginia in Richmond; the Texas Transplant Institute in San Antonio; the School of Dentistry and the Division of Hematology-Oncology at the University of California at Los Angeles; and Amgen in Thousand Oaks, Calif.

UNC Lineberger is one of 38 comprehensive cancer centers designated by the National Cancer Institute. Center faculty members treat cancer patients, conduct research into the causes of cancer, direct statewide programs in cancer prevention and train future physicians, nurses, scientists and public health professionals.


Story Source:

The above story is based on materials provided by University Of North Carolina At Chapel Hill. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina At Chapel Hill. "Medication May Reduce Incidence, Severity Of Mouth Sores In Some Cancer Patients: Study." ScienceDaily. ScienceDaily, 28 December 2004. <www.sciencedaily.com/releases/2004/12/041219182232.htm>.
University Of North Carolina At Chapel Hill. (2004, December 28). Medication May Reduce Incidence, Severity Of Mouth Sores In Some Cancer Patients: Study. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2004/12/041219182232.htm
University Of North Carolina At Chapel Hill. "Medication May Reduce Incidence, Severity Of Mouth Sores In Some Cancer Patients: Study." ScienceDaily. www.sciencedaily.com/releases/2004/12/041219182232.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins